Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.45 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413545 | 0.87 | NPC1 (0.43) | FAAHNPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL4419245 | 0.86 | NPC1 (0.46) | NPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL4430237 | 0.85 | FAAH (0.51) | FAAHMTORDPP4DPP8NPC1 | |
| SCHEMBL4417838 | 0.84 | FAAH (0.42) | FAAHMTORNPC1RAB9AMAPT | |
| SCHEMBL4417584 | 0.82 | KDM4E (0.47) | MTORNPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL4421360 | 0.82 | NPC1 (0.43) | MTORNPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL4422629 | 0.82 | ALDH1A1 (0.41) | FAAHMTORNPC1RAB9AMAPT | |
| SCHEMBL4423907 | 0.82 | HTT (0.50) | MTORNPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL4412370 | 0.82 | L3MBTL1 (0.44) | NPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL4413699 | 0.82 | GAA (0.48) | NPC1RAB9AMAPTL3MBTL1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-7473787-B2 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | FAAH 2866/4885MTOR 1652/4885DPP4 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.